Inivata Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 85
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $35M
Latest Deal Amount
  • Investors
  • 12

Inivata General Information

Description

Developer of a liquid biopsy platform designed to unlock essential genomic information from a simple blood draw to guide and personalize cancer treatment. The company's platform focuses on harnessing the potential of circulating tumor DNA (ctDNA) analysis, monitor response, and detect relapse, enabling clinicians to make more informed treatment decisions for advanced NSCLC patients.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Glenn Berge Building
  • Babraham Research Campus, Babraham
  • Cambridge CB22 3FH
  • England, United Kingdom
+44 01223 000000

Inivata Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inivata Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 04-Feb-2021 $35M 00000 Completed Generating Revenue
4. Corporate 03-Jun-2020 000.00 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series B) 28-Mar-2019 000.00 00000 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 26-Jan-2016 $45.6M $52.2M 0000 Completed Generating Revenue
1. Early Stage VC 23-Sep-2014 $6.55M $6.55M 000 Completed Startup
To view Inivata’s complete valuation and funding history, request access »

Inivata Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C1 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series C1 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Deferred 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A 16,591,575 $0.000012 7% $2.33 $2.33 1x $2.33 31.03%
Preference 4,000,000 $0.000012 5% $1.23 $1.23 1x $1.23 7.48%
To view Inivata’s complete cap table history, request access »

Inivata Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a liquid biopsy platform designed to unlock essential genomic information from a simple blood draw to guide
Biotechnology
Cambridge, United Kingdom
85 As of 2021
00000
00000000000 00000

0000000

lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
0000000000000
Leeds, United Kingdom
00 As of 0000
00.00
00.00 0000-00-00
0000000000 0 00.00

00000000

rcitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehen
0000000000000
Castel Maggiore, Italy
000 As of 0000
000.00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inivata Competitors (59)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abcodia Venture Capital-Backed Leeds, United Kingdom 00 00.00 0000000000 0 00.00
00000000 0000000 0 Formerly VC-backed Castel Maggiore, Italy 000 000.00 000000&0 000.00
00000000 Venture Capital-Backed San Francisco, CA 000 00000 00000000000 00000
00000000 000000000 Venture Capital-Backed Wuxi, China 00000 00000000000 00000
000000000 00000000 Formerly VC-backed Billerica, MA 00 00000 000000&0 00000
You’re viewing 5 of 59 competitors. Get the full list »

Inivata Executive Team (19)

Name Title Board Seat Contact Info
Clive Morris MD Chief Executive Officer & Board Member
Tim Shannon Chief Financial Officer
Alan Schafer Ph.D Chief Technology Officer
Charlie Kesinger Chief Information Officer
Nitzan Rosenfeld Ph.D Co-Founder & Chief Scientific Officer
You’re viewing 5 of 19 executive team members. Get the full list »

Inivata Board Members (13)

Name Representing Role Since
Clive Morris MD Inivata Chief Executive Officer & Board Member 000 0000
Craig Richardson Ph.D IP Group Board Member 000 0000
Douglas VanOort NeoGenomics Laboratories Board Member 000 0000
Jeffrey Buchalter Self Non-Executive Chairman 000 0000
Peter Wrighton-Smith Ph.D Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Inivata Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inivata Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
Janus Henderson Investors Hedge Fund Minority 000 0000 000000 0
Soleus Capital PE/Buyout Minority 000 0000 000000 0
NeoGenomics Laboratories Corporation Minority 000 0000 000000 0
RT Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »